Research overview based on the cited scientific literature.

Goal: Support immune modulation and thymic function markers based on preclinical observations[1][2].

Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) shortterm or −80 °C (−112 °F) longterm in dry, dark conditions; minimize moisture exposure[10].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~1 week or prepare aliquots and freeze to extend stability.
Allow vials to reach room temperature before opening to reduce condensation uptake.

Vilon belongs to a class of short bioregulatory peptides developed through Russian gerontology research[4]. In vitro studies demonstrate that the LysGlu dipeptide can modulate lymphocyte populations and cytokine gene expression. Specifically, Vilon has been observed to increase CD5+ cell counts in thymus cell cultures[1] and upregulate interleukin2 (IL2) mRNA expression in splenocyte preparations[2]. Additional preclinical work suggests effects on TGFβ1 and vascular permeability in renal models[3]. A regimen discussed for another peptide does not establish a Vilon administration schedule; this overview does not recommend personal treatment cycles.

Observations from preclinical literature.
Supports immune cell marker expression (CD5+ lymphocytes) and IL2 gene activity in cell culture models[1][2].
May modulate inflammatory cytokines such as TGFβ1 under experimental renal stress conditions[3].
Early mouse studies suggest potential effects on tumor growth inhibition and lifespan extension, though human data remain limited[6].
Generally well tolerated in preclinical settings; occasional mild injectionsite reactions (redness/itch) may occur with subcutaneous administration.